SS31

SS-31, also known as Elamipretide or MTP-131, is a mitochondria-targeted aromatic-cationic tetrapeptide designed to interact with cardiolipin within the inner mitochondrial membrane. By targeting the mitochondrial membrane directly, SS-31 has been investigated for its potential to preserve mitochondrial structure, support oxidative phosphorylation, and reduce mitochondrial oxidative stress.

How does SS-31 work?

SS-31 selectively localizes to the inner mitochondrial membrane, where it binds to cardiolipin, an important phospholipid involved in maintaining mitochondrial membrane structure and respiratory-chain organization. Research indicates that this interaction can help stabilize mitochondrial structures and improve the efficiency of electron transport and energy production while reducing excessive reactive oxygen species generation.

How is SS-31 Used?

SS-31 has been investigated in both preclinical and clinical research involving mitochondrial dysfunction, cardiovascular conditions, skeletal-muscle metabolism, and rare mitochondrial diseases. Clinical studies have evaluated intravenous and subcutaneous administration depending on the indication and research protocol.

Research has included primary mitochondrial myopathy, heart failure, renal ischemia, myocardial injury, and Barth syndrome. The compound’s mitochondria-targeting properties make it particularly relevant to research examining cellular energy production and mitochondrial integrity.

Benefits:

Mitochondrial Function: SS-31 has been investigated for its ability to preserve mitochondrial structure and support oxidative phosphorylation. Human research has demonstrated measurable effects on mitochondrial energetic capacity in certain study populations.

Cardiolipin Interaction: One of the defining characteristics of SS-31 is its ability to bind cardiolipin within the inner mitochondrial membrane. This interaction is central to research investigating mitochondrial membrane stability and respiratory-chain function.

Cellular Energy Research: By influencing mitochondrial electron transport and oxidative phosphorylation, SS-31 has been studied as a potential means of improving mitochondrial energy production and cellular bioenergetics.

Oxidative Stress Research: Experimental studies have investigated SS-31 for its potential to reduce mitochondrial oxidative stress and protect cellular structures from damage associated with impaired mitochondrial function.

Mitochondrial Disease Research: Elamipretide has undergone clinical investigation in primary mitochondrial myopathies and other mitochondrial disorders. However, a large Phase 3 trial in primary mitochondrial myopathy did not demonstrate improvement in its primary measures of walking distance or fatigue after 24 weeks.

Cardiovascular Research: SS-31 has also been evaluated in cardiovascular research, including heart failure and ischemia-reperfusion injury. Early clinical studies have provided evidence of biological activity, although efficacy varies according to the condition and study design.

Barth Syndrome Research: Elamipretide has particular relevance to Barth syndrome, a rare mitochondrial disorder involving abnormal cardiolipin metabolism. In 2025, the FDA granted accelerated approval for elamipretide for Barth syndrome, making it the first therapy specifically targeting the mitochondrial cause of the disease.

Research Considerations:

The clinical evidence for SS-31 is mixed and highly dependent on the condition being studied. For example, the Phase 3 MMPOWER-3 trial in primary mitochondrial myopathy did not meet its primary endpoints for six-minute walk distance or fatigue, despite demonstrating that subcutaneous treatment was generally well tolerated.

At the same time, research in other mitochondrial conditions has produced encouraging findings. In Barth syndrome, the initial randomized trial did not meet its primary endpoints, although subsequent open-label follow-up reported improvements in walking distance and symptom scores. The FDA’s accelerated approval therefore requires confirmatory evidence.

These findings demonstrate why SS-31 should not be marketed as a universal mitochondrial “booster” or general anti-aging treatment. Its effects and clinical relevance depend on the specific disease, formulation, dose, and treatment setting.

Dosage:

SS-31 dosing has varied substantially across clinical studies and depends on the formulation, route of administration, and medical indication. For example, clinical trials in primary mitochondrial myopathy investigated 40 mg administered subcutaneously once daily, while earlier studies used intravenous infusion protocols. These research protocols should not be generalized to other applications.

Conclusions:

SS-31 (Elamipretide) is a mitochondria-targeted tetrapeptide with a distinctive mechanism centered on cardiolipin within the mitochondrial inner membrane. Its ability to interact directly with mitochondrial membranes has made it an important subject of research into oxidative phosphorylation, cellular energy production, oxidative stress, and mitochondrial dysfunction.

Clinical research has produced both promising and inconclusive results across different diseases. Its most significant clinical development to date is its FDA accelerated approval for Barth syndrome, while trials in other mitochondrial disorders have produced mixed efficacy results.

SS-31 should therefore be presented according to the specific evidence supporting each application rather than as a broadly established treatment for mitochondrial dysfunction.

SS-31 is presented here for research and educational purposes and should not be considered a substitute for professional medical advice or approved medical treatment.